Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management (CBL-0201WR Phase 2). The study will evaluate CBL-514 in combination with Zepbound® (Eli Lilly) in subjects with obesity or overweight ... About CBL-514.
The Central Bank of Lithuania (CBL) recently reminded participants in the market that this is not merely a recommendation, but a mandatory requirement, regional media noted this week.
). 2026 FirstQuarter Report. CONSOLIDATED STATEMENT OF FINANCIAL POSITION. AsofSeptember30, 2025 (Expressed in B$000, unaudited). CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME. For theperiod ended September 30, 2025 ...Sep 30. 2025.